SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?


To: John Zwiener who wrote (897)2/3/1998 3:02:00 AM
From: luis a. garcia  Read Replies (2) | Respond to of 1115
 
Break fluid right it makes more sense... I have been wanting to ask but afraid of the answer... How do we translate P values to days of improvement??? can you elaborate.
luis



To: John Zwiener who wrote (897)2/3/1998 8:25:00 AM
From: Henry Volquardsen  Respond to of 1115
 
John,

They look like they want too much for the loan. My first impulse is to go to another lender.

My first instinct is to say they are asking to much as well. It is tough to make a clear determination until we know more of the details. But forget their wording for a moment and look at what little we know of the proposal so far. They are offering to lend the company funds equivalent to double it's net worth. In exchange for this they want to have significant if not controling interest in the board. If you look at other financings of development stage companies I don't believe such an arrangement is uncommon. As part of my own investing I get involved with a lot of venture capital and development stage financing deals. It is not uncommon at all for a lender at this stage to demand significant representation or even a controlling stake. Going to another lender for such a large amount of money would most likely, imho, also come with some pretty tight strings.

I don't say this as a defense of this deal or of HealthMed as we clearly don't know enough about either yet. Just food for discussion.